Skip to content

OÜ PharmaFour

Registry code (registrikood) 14518678Private limited company (Osaühing)VAT EE102129067Activity (EMTAK 47731): Ravimite jaemüükActive

Tallinn, Harju County · Financial data: annual reports up to 2025; tax data up to 2026 Q3

Revenue (2025)
€5.1M
▲ 23.1% vs 2024
Profit before tax (2025)
-€30k
Employees, FTE (2025)
6
State taxes paid, last 4 quarters
€47k

Revenue, profit and employees, 2019–2025

€722k2019€2.8M2020€3.3M2021€3.2M2022€3.4M2023€4.1M2024€5.1M2025
YearRevenue (müügitulu)Operating profit (ärikasum)Net profitEquity (omakapital)Employees, FTE
2019€722,365-€102,222-€110,492-€107,9925
2020€2,767,163-€212,744-€224,207-€332,1997
2021€3,262,115€176,898€165,465-€166,7341
2022€3,226,907€16,922€5,230-€161,5052
2023€3,364,198€44,745€32,328-€129,1773
2024€4,127,898€23,096€21,681-€107,4963
2025€5,080,497-€29,597-€29,593-€137,0896

Balance sheet summary

YearCashTotal assetsCurrent liabilitiesNon-current liabilitiesEquity
2019€45,994€366,260€474,252—-€107,992
2020€76,854€1,550,261€1,882,460—-€332,199
2021€79,178€1,395,616€1,562,350—-€166,734
2022€258,804€1,463,885€1,625,390—-€161,505
2023€381,400€1,516,011€1,645,188—-€129,177
2024€62,205€1,045,032€1,152,528—-€107,496
2025€191,216€1,218,763€1,355,852—-€137,089

Calculated ratios

Net profit margin = net profit ÷ revenue. Equity ratio = equity ÷ total assets. Seedata sources & methodology for how each figure is derived.

Quarterly tax and turnover data (EMTA)

QuarterState taxes paidWage taxesTurnoverEmployees
2022 Q1€304€4,856€809,7373
2022 Q2€4,893€6,236€784,4684
2022 Q3€9,136€12,624€695,2014
2022 Q4€5,635€11,823€923,3825
2023 Q1€8,385€11,868€811,6745
2023 Q2€8,282€12,048€787,4215
2023 Q3€8,682€12,832€743,3746
2023 Q4€9,745€12,430€948,6106
2024 Q1€7,276€12,167€940,6406
2024 Q2€0€12,395€1,041,9456
2024 Q3€6,980€14,733€870,0954
2024 Q4€0€9,085€1,269,69110
2025 Q1€3,674€16,570€1,004,60912
2025 Q2€16,089€24,164€1,306,58513
2025 Q3€15,791€26,744€1,185,14113
2025 Q4€15,577€25,329€1,427,84513
2026 Q1€13,639€26,754€1,380,66521
2026 Q2€10,831€20,327€1,335,30724
2026 Q3€7,312€18,930€1,351,00725

Source: EMTA quarterly published data, as of 10 October 2026. Covers state taxes and wage taxes actually paid and turnover and employee counts as declared by the company, not the annual report figures above.

About this data

In the 2025 financial year (period 1 January 2025–31 December 2025), OÜ PharmaFour reported revenue of €5,080,497.

The company recorded a net loss of €29,593 in the 2025 financial year.

Revenue increased by 23.1% from €4,127,898 in 2024 to €5,080,497 in 2025.

Revenue grew at a compound annual rate of 38.4% between 2019 and 2025.

Equity accounted for -11.2% of total assets of €1,218,763 at the end of the 2025 reporting period.

With 6 full-time-equivalent employees in 2025, revenue per employee was €846,750.

Across the 4 most recent quarters declared to EMTA, up to Q3 2026, OÜ PharmaFour reported €5,494,824 in turnover.

EMTA recorded 25 employees for the quarter ending Q3 2026, compared with 6 full-time-equivalent employees in the 2025 annual report.

Browse

Source

Source: Estonian e-Business Register open data (Centre of Registers and Information Systems, RIK), licence CC BY-SA 4.0, modified; Estonian Tax and Customs Board (EMTA) quarterly data. Downloaded 2026-11-16. This is not an official register extract — see ariregister.rik.ee.

Company data on this site is available under CC BY-SA 4.0.

To request a correction or the removal of this page, use the contact form. Removal requests are handled within 30 days, no justification required.